Facilitated subcutaneous immunoglobulin treatment patterns in pediatric patients with primary immunodeficiency...

Area of Science:

• Immunology
• Pediatrics
• Pharmacology

Background:

• Primary immunodeficiency diseases (PIDs) are a group of genetic disorders affecting the immune system.
• Subcutaneous immunoglobulin (SCIG) replacement therapy is a common treatment for PIDs.
• Hyaluronidase-facilitated SCIG (fSCIG) allows for larger volumes of immunoglobulin to be administered subcutaneously.

Purpose of the Study:

• To investigate real-world treatment patterns of fSCIG in pediatric patients with PIDs in Poland.
• To assess the feasibility and clinical outcomes of fSCIG in this population.
• To identify optimal fSCIG administration parameters for children and adolescents.

Main Methods:

• Retrospective study of 28 pediatric patients (aged ≤18 years) with PIDs receiving fSCIG.
• Extraction of clinical and demographic data, fSCIG treatment parameters, and clinical outcomes from medical records.
• Analysis of infusion frequency, duration, and number of infusion sites used.

Main Results:

• 18 participants (64.3%) initiated fSCIG with a ramp-up period (median duration: 35.5 days).
• Most patients (96.4%) received fSCIG every 4 weeks; one patient received it every 3 weeks.
• The majority of patients (89.3%) used a single infusion site, and no serious bacterial infections were reported.

Conclusions:

• fSCIG is a feasible and safe treatment option for pediatric patients with PIDs in Poland.
• fSCIG can be effectively administered every 3-4 weeks using a single infusion site.
• Treatment parameters for fSCIG demonstrate flexibility, allowing for individualized patient care.